Holen Sie sich die Stockscreener-App
140.64
2.60%
3.56
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$137.08
Offen:
$138
24-Stunden-Volumen:
1.77M
Relative Volume:
1.21
Marktkapitalisierung:
$20.59B
Einnahmen:
$9.61B
Nettoeinkommen (Verlust:
$1.62B
KGV:
12.70
EPS:
11.07
Netto-Cashflow:
$1.77B
1W Leistung:
+2.41%
1M Leistung:
-0.24%
6M Leistung:
-31.79%
1J Leistung:
-36.39%
1-Tages-Spanne:
$137.56
$141.50
1-Wochen-Bereich:
$135.02
$141.50
52-Wochen-Spanne:
$128.51
$238.00
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
140.64 | 20.59B | 9.61B | 1.62B | 1.77B | 11.07 |
|
LLY
Lilly Eli Co
|
873.68 | 830.35B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
88.08 | 390.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
ABBV
Abbvie Inc
|
202.08 | 356.74B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.30 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
89.50 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Allianz Asset Management GmbH Has $81.96 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Options Trading: A Deep Dive into Market Sentiment - Benzinga
Biogen Inc. (NASDAQ:BIIB) Stock Position Increased by Meitav Investment House Ltd. - MarketBeat
Ieq Capital LLC Buys 55,514 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Stock Is Mutating Into a Value Play - MSN
Biogen Inc. (NASDAQ:BIIB) Shares Sold by ICICI Prudential Asset Management Co Ltd - MarketBeat
What is Wedbush's Forecast for Biogen Q1 Earnings? - MarketBeat
Alberta Investment Management Corp Grows Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Takes $751,000 Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Fenwick Represents Stoke Therapeutics in Strategic Collaboration with BioGen - Fenwick & West LLP
New York State Teachers Retirement System Sells 6,673 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen, Stoke Partner on Zorevunersen in Dravet Syndrome - Contract Pharma
Biogen's (BIIB) "Neutral" Rating Reiterated at Piper Sandler - MarketBeat
Biogen bags rights to epilepsy drug from Stoke in $550m deal - pharmaphorum
We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative - Simply Wall St
Kentucky Retirement Systems Insurance Trust Fund Raises Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen takes territorial rights to Stoke’s Dravet program: Deals Report - BioCentury
Stoke Gets Runway, Biogen A Late-Stage Asset In Epilepsy Collaboration - News & Insights
Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally - MSN
Oppenheimer maintains Biogen Outperform with $255 target - Investing.com
Biogen stock price target cut to $159 by Bernstein SocGen - Investing.com Australia
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal - Yahoo Finance
Biogen continues dealmaking buzz with Stoke Therapeutics - The Business Journals
Biogen buys rights to Stoke’s rare epilepsy drug - BioPharma Dive
Biogen Bets Up to $550 Million for Rights to Epilepsy Drug - Bloomberg
Bernstein Adjusts Price Target on Biogen to $159 From $160, Keeps Market Perform Rating - Marketscreener.com
Biogen partners with Stoke Therapeutics to sell severe epilepsy drug - STAT
Biogen and Stoke Thera ink deal on zorevunersen development - The Pharma Letter
Biogen and Stoke Therapeutics collaborate to develop Dravet syndrome treatment globally - Seeking Alpha
Piper Sandler cuts Biogen price target to $135, keeps neutral rating - Investing.com India
Biogen, Stoke partner for Dravet syndrome treatment - Investing.com
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy - MarketWatch
Biogen partners with Stoke Therapeutics on drug for severe epilepsy - STAT
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments - Biogen | Investor Relations
Major Epilepsy Treatment Breakthrough: Biogen Acquires Rights to FDA-Designated Therapy in Massive Deal - StockTitan
Biogen's SWOT analysis: stock faces challenges amid pipeline potential - Investing.com
Rhumbline Advisers Has $41.07 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Banque Pictet & Cie SA Raises Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Cantor Fitzgerald Reduces Earnings Estimates for Biogen - MarketBeat
Biogen's (BIIB) "Hold" Rating Reiterated at Needham & Company LLC - MarketBeat
Morgan Stanley Has Lowered Expectations for Biogen (NASDAQ:BIIB) Stock Price - MarketBeat
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Acquires New Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
The Goldman Sachs Group Cuts Biogen (NASDAQ:BIIB) Price Target to $245.00 - MarketBeat
Stephens Inc. AR Sells 2,270 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Q1 Earnings Estimate for Biogen Issued By Leerink Partnrs - MarketBeat
19,574 Shares in Biogen Inc. (NASDAQ:BIIB) Acquired by Strategic Financial Concepts LLC - MarketBeat
Viral Gene Therapy Market May See a Big Move | Biogen, Novartis AG, Gilead Sciences - openPR
Vontobel Holding Ltd. Increases Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Reports Q4 and Full-Year 2024 Results: Strong EPS Growth Amid Revenue Challenges - BSA bureau
William Blair Issues Optimistic Estimate for Biogen Earnings - MarketBeat
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.61%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):